Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Un estudio de BI-1206 en combinación con rituximab en sujetos con linfoma no Hodgkin de células B indolente

1 de octubre de 2026 actualizado por: BioInvent International AB

Ensayo clínico de fase 1/2a de BI-1206, un anticuerpo monoclonal contra CD32b (FcYRIIB), en combinación con rituximab en sujetos con linfoma no Hodgkin de células B indolente que ha recaído o es refractario a rituximab

Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination with Rituximab with or without Acalabrutinib in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That has Relapsed or is Refractory to Rituximab

Descripción general del estudio

Descripción detallada

This is a Phase 1/2a, multicenter, dose escalation, consecutive-cohort, open-label trial of BI-1206 in combination with rituximab with or without acalabrutinib in subjects with indolent relapsed or refractory B-cell NHL, sub-types FL (except FL grade 3B), MZL, and MCL.

Phase 2a, consists of signal seeking cohorts followed by a randomized, parallel, two-arm dose optimization.

The trial consists of 2 main parts:

Phase 1

- Dose Escalation, with two different Arms assessing IV or SC dosing of BI-1206 in combination with rituximab, with dose escalation cohorts and selection of the IV and SC doses of BI-1206 for Phase 2a

Phase 2a

  • Dose Expansion, with one expansion cohort evaluating the selected IV dose of BI-1206 in combination with rituximab
  • Signal Seeking, assessing IV and SC dosing of BI-1206 in combination with rituximab and acalabrutinib. The Signal Seeking will consist of a Safety Run-in and an Expansion
  • Dose Optimization to select the recommended dose of BI-1206 in combination with rituximab and acalabrutinib

Tipo de estudio

Intervencionista

Inscripción (Estimado)

140

Fase

  • Fase 2
  • Fase 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Copia de seguridad de contactos de estudio

Ubicaciones de estudio

      • Stuttgart, Alemania
        • Retirado
        • Robert Bosch Hospital, Dep of Hematology, Oncology and Palliative care
    • Hesse
      • Frankfurt am Main, Hesse, Alemania
        • Aún no reclutando
        • Krankenhaus Nordwest Klinik für Onkologie und Hämatologie
        • Investigador principal:
          • Eckhart Weidmann, MD
        • Contacto:
      • Curitiba, Brasil
        • Aún no reclutando
        • Hospital Erasto Gaertner - Liga Paranaense de Combate ao Câncer
        • Contacto:
        • Investigador principal:
          • Eduardo Munhoz, MD
      • Rio de Janeiro, Brasil
      • São Paulo, Brasil
        • Aún no reclutando
        • Hospital Samaritano
        • Contacto:
        • Investigador principal:
          • Carlos Chiattone, MD
      • São Paulo, Brasil
        • Aún no reclutando
        • Hospital Sírio-Libanês
        • Investigador principal:
          • Ana Rita Da Fonseca, MD
        • Contacto:
      • São Paulo, Brasil
        • Aún no reclutando
        • Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
        • Contacto:
        • Investigador principal:
          • Juliana Pereira, MD
      • São Paulo, Brasil
        • Reclutamiento
        • A.C. Camargo Cancer Center
        • Investigador principal:
          • Ana Costa Cordeiro, MD
        • Contacto:
      • São Paulo, Brasil
      • São Paulo, Brasil
        • Reclutamiento
        • Hospital Israelita Albert Einstein
        • Investigador principal:
          • Guilherme Perini, MD
        • Contacto:
    • Estado de Bahia
      • Salvador, Estado de Bahia, Brasil
        • Reclutamiento
        • Hospital São Rafael
        • Contacto:
        • Investigador principal:
          • Ana Luiza Schriefer, MD
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brasil
        • Reclutamiento
        • Hospital de Clínicas de Porto Alegre
        • Investigador principal:
          • Laura Maria Fogliatto, MD
        • Contacto:
      • Barcelona, España
        • Reclutamiento
        • Institut Català d'Oncologia, L'Hospitalet de Llobregat
        • Investigador principal:
          • Eva Domingo Domenech, MD
        • Contacto:
      • Madrid, España
        • Reclutamiento
        • University Hospital Fundacion Jimenez Diaz
        • Investigador principal:
          • Raul Cordoba Mascunano, MD
        • Contacto:
    • Barcelona
      • Badalona, Barcelona, España
        • Reclutamiento
        • Hospital ICO, Trias i Pujol
        • Investigador principal:
          • Juan Manuel Sancho Cia, MA
        • Contacto:
      • Barcelona, Barcelona, España
        • Reclutamiento
        • Hospital Universitari Vall d'Hebron
        • Investigador principal:
          • Pablo Abrisqueta Costa, MD
        • Contacto:
      • Barcelona, Barcelona, España
        • Reclutamiento
        • Hospital de la Santa Creu i Sant Pau, Dep Hematologia
        • Contacto:
        • Investigador principal:
          • Sara Miqueleiz Alamos, MD
    • Madrid
      • Madrid, Madrid, España
        • Reclutamiento
        • Hospital Universitario HM Sanchinarro
        • Contacto:
        • Investigador principal:
          • Augustin Penedo Coello, MD
      • Madrid, Madrid, España
        • Reclutamiento
        • Hospital General Universitario Gregorio Marañon-Oncología Médica
        • Investigador principal:
          • Mariana Bastos Oreiro, MD
        • Contacto:
    • Murcia
      • Murcia, Murcia, España
        • Aún no reclutando
        • Hospital Universitario Virgen de la Arrixaca
        • Investigador principal:
          • Joaquin Gomez Espuch, MD
        • Contacto:
    • Seville
      • Seville, Seville, España
        • Reclutamiento
        • Hospital University Virgen Macarene
        • Investigador principal:
          • Sergio Ortegon Alcaide, MD
        • Contacto:
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30322
        • Activo, no reclutando
        • Emory University Hospital
    • Kentucky
      • Louisville, Kentucky, Estados Unidos, 40207
        • Reclutamiento
        • Norton Cancer Institute - St. Matthews 3991 Dutchmans Lane Medical Plaza II, Suite 405
        • Investigador principal:
          • Don Stevens, MD
      • Grudziądz, Polonia, 86-300
        • Terminado
        • Szpital Specjlistyczny
      • Krakow, Polonia
        • Terminado
        • Małopolskie Centrum Medyczne
      • Lund, Suecia, SE-22185
        • Terminado
        • Department of Oncology, Skåne University Hospital
    • Sweden
      • Uppsala, Sweden, Suecia, 751 85
        • Terminado
        • Department of Oncology, Academical Hospital

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Are ≥ 18 years of age by initiation of study treatment.
  2. Have B-cell NHL proven by histology, with histological subtypes limited to follicular lymphoma (FL) (except FL grade 3B), MCL and marginal zone lymphoma (MZL)
  3. Have measurable nodal disease
  4. Are willing to undergo lymph node biopsies or biopsies of other involved tissue
  5. Have relapsed disease or disease refractory to conventional treatment or for which no standard therapy exists
  6. Have received at least one line of conventional previous therapy which must include at least one rituximab-based regimen
  7. Have a life expectancy of at least 12 weeks
  8. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
  9. Have CD20+ malignancy
  10. Have hematological and biochemical indices within prespecified ranges

Exclusion Criteria:

  1. Have had an allogenic bone marrow or stem cell transplant within 12 months

  2. Have presence of active chronic graft versus host disease

  3. Have current leptomeningeal lymphoma or compromise of the central nervous system

  4. Have transformed lymphoma from a pre-existing indolent lymphoma

  5. Have Waldenstrom's Macroglobulinemia or FL grade 3B,

  6. Need systemic doses of prednisolone >10 mg daily (or equipotent doses of other corticosteroids) while on the study trial other than as pre-medication.

  7. Have known or suspected hypersensitivity to rituximab or BI-1206

  8. Have cardiac or renal amyloid light-chain amyloidosis

  9. Have received any of the following:

    1. Chemotherapy or small molecule products with 2 weeks of first dose of BI-1206
    2. Radiotherapy (except for focal symptomatic control of lymphadenopathy) within 4 weeks
    3. Immunotherapy within 8 weeks
    4. Previous lines of treatment containing BTK inhibitors for Subjects receiving BI-1206 in combination with rituximab and acalabrutinib
  10. Have ongoing toxic manifestations of previous treatments.

  11. Have the ability to become pregnant (or already pregnant or lactating/breastfeeding).

  12. Have had major surgery from which the subject has not yet recovered.

  13. Are at high medical risk because of non-malignant systemic disease including active infection on treatment with antibiotics, antifungals or antivirals.

  14. Are serologically positive for hepatitis B, hepatitis C or human immunodeficiency virus (HIV).

  15. Have an active, known or suspected autoimmune disease.

  16. Have concurrent congestive heart failure, prior history of class III/ IV cardiac disease (New York Heart Association [NYHA])

  17. Have current malignancies of other types

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: No aleatorizado
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: BI-1206 IV Dose Escalation

Standard 3+3 Dose-Escalation of BI-1206 IV in combination with Rituximab

BI-1206 150 mg / 225 mg Subcutaneous injection

BI-1206 50 mg /100 mg Intravenous infusion

Rituximab 375 mg/m2, as per SmPC

Otros nombres:
  • Ruxencia
Experimental: BI-1206 SC Dose Escalation

Adaptive Dose Escalation of BI-1206 SC (Bayesian logistic regression model (BLRM) in combination with Rituximab

BI-1206 150 mg / 225 mg Subcutaneous injection

BI-1206 50 mg /100 mg Intravenous infusion

Rituximab 375 mg/m2, as per SmPC

Otros nombres:
  • Ruxencia
Experimental: Phase 2a IV Dose expansion

BI-1206 IV in Combination with Rituximab

BI-1206 150 mg / 225 mg Subcutaneous injection

BI-1206 50 mg /100 mg Intravenous infusion

Rituximab 375 mg/m2, as per SmPC

Otros nombres:
  • Ruxencia
Experimental: Phase 2a SC Signal seeking

SC Arm, BI-1206 in Combination with Rituximab and Acalabrutinib

BI-1206 150 mg / 225 mg Subcutaneous injection

BI-1206 50 mg /100 mg Intravenous infusion

Rituximab 375 mg/m2, as per SmPC

Otros nombres:
  • Ruxencia

Acalabrutinib 100 mg orally as per SmPC

Otros nombres:
  • Calcuencia
Experimental: Phase 2a IV Signal Seeking

IV Arm, BI-1206 in Combination with Rituximab and Acalabrutinib

BI-1206 150 mg / 225 mg Subcutaneous injection

BI-1206 50 mg /100 mg Intravenous infusion

Rituximab 375 mg/m2, as per SmPC

Otros nombres:
  • Ruxencia

Acalabrutinib 100 mg orally as per SmPC

Otros nombres:
  • Calcuencia

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Documenting AEs and SAEs and determining causality in relation to BI-1206 and/or rituximab and/or acalabrutinib
Periodo de tiempo: During the 28-day treatment period on induction therapy

Assess the safety and tolerability profile of BI-1206 when administered intravenously (IV) or subcutaneously (SC) in combination with rituximab or rituximab and acalabrutinib in subjects with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL), subtypes follicular lymphoma (FL)(except FL grade 3B), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL). Assessment will be done according to National Cancer Institute (NCI-CTCAE) criteria v. 5.0.

During the 28-day treatment period on induction therapy
Determining the MTD of BI-1206 at the same dose level experiencing a BI-1206 or Rituximab-related or possibly related dose-limiting toxicity (DLT)
Periodo de tiempo: During the 28-day treatment period on induction therapy

Phase 1:

Select the recommended Phase 2 dose (RP2D) by establishing the maximum tolerated dose (MTD) of BI-1206 given once weekly for 4 weeks, via IV infusion or SC injection in combination with rituximab.

During the 28-day treatment period on induction therapy
Determine the recommended dose of BI-1206 in combination with rituximab and acalabrutinib
Periodo de tiempo: During the 28-day treatment period on induction therapy

Phase 2a:

Select the recommended dose of BI-1206 in combination with rituximab and acalabrutinib.

During the 28-day treatment period on induction therapy

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Evaluation of PK parameters for BI-1206
Periodo de tiempo: Up to 1 year

PK parameters assessed will include AUC, Cmax, time to Cmax and t1/2 of BI-1206 when administered IV or SC

Up to 1 year
Evaluation of ADA (immunogenicity) response to BI-1206
Periodo de tiempo: Up to 1 year

Assess the incidence and titre of antidrug antibodies of BI-1206 in serum when administered IV or SC in combination with rituximab or rituximab and acalabrutinib.

Up to 1 year
Measurement of peripheral blood B-lymphocytes depletion
Periodo de tiempo: Up to 1 year

Evaluate the effect of BI-1206 administered IV or SC in combination with rituximab or rituximab and acalabrutinib measuring B Lymphocytes CD19+ (absolute value) as part of hematology assessment to determine the level of peripheral blood B lymphocyte depletion.

Up to 1 year
Assessment of overall response rate (ORR) according to the response criteria for malignant lymphoma (Cheson, 2014).
Periodo de tiempo: Up to 1 year

Assess possible anti-tumor activity of BI-1206 administered IV or SC in combination with rituximab or rituximab and acalabrutinib at Week 6 after first dose of BI-1206 and for subjects who continue during maintenance therapy.

Up to 1 year

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Expression levels of CD32b protein
Periodo de tiempo: Up to 1 year

To investigate CD32b protein expression levels using flow cytometry to evaluate any potential correlation with clinical responses. Change from baseline expression levels will be summarized descriptively by dose cohort and/or response to treatment.

Up to 1 year
Assessment of Patient Reported Outcomes using the NCI PRO-CTCAE questionnaire
Periodo de tiempo: Up to 1 year

The NCI PRO-CTCAE will be used to evaluate symptomatic toxicities reported by patients. The questionnaire characterizes the frequency, severity, interference, and presence/absence of symptomatic toxicities, all toxicities that can be meaningfully reported from the patient perspective.

Responses are scored from 0 to 4 (or 0/1 for absent/present). Scores for each attribute (frequency, severity and/or interference) will be presented descriptively (e.g. summary statistics or graphical presentations).

Up to 1 year
Expression levels of CD32b and/or other immunological markers
Periodo de tiempo: Up to 1 year

Perform whole-transcriptome, quantitative polymerase chain reaction (qPCR) and/or IHC analysis of lymph node biopsies to evaluate potential correlation with clinical responses.

Up to 1 year
Measurement of serum cytokines levels and/or soluble CD32b.
Periodo de tiempo: Up to 1 year

Study the potential cause of infusion related reactions (IRRs), such as cytokine release signs, C-reactive protein (CRP) and/or soluble CD32b.

Up to 1 year

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

16 de mayo de 2018

Finalización primaria (Estimado)

30 de septiembre de 2027

Finalización del estudio (Estimado)

30 de septiembre de 2027

Fechas de registro del estudio

Enviado por primera vez

17 de mayo de 2018

Primero enviado que cumplió con los criterios de control de calidad

18 de junio de 2018

Publicado por primera vez (Actual)

27 de junio de 2018

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

2 de octubre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

1 de octubre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

All information concerning the product as well as any matter concerning the operation of the Sponsor, such as clinical indications for the drug, its formula, methods of manufacture and other scientific data relating to it, that have been provided by the Sponsor and are unpublished, are confidential and must remain the sole property of the Sponsor. The Investigator will agree to use the information only for the purposes of carrying out this study and for no other purpose unless prior written permission from the Sponsor is obtained.

Marco de tiempo para compartir IPD

Within one year from end of study

Criterios de acceso compartido de IPD

Paper copy of CSR

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO
  • RSC

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir